Interagency coordination in drug research and regulation. Hearings before the Subcommittee on Reorganization and International Organizations of the Committee on Government Operations, United States Senate, Eighty-eighth Congress, first session. Agency coordination study, pursuant to S. Res. 27, 88th Cong. Review of cooperation on drug policies among Food and Drug Administration, National Institutes of Health, Veterans' Administration, and other agencies. Mar. 20-June 26, 1963.

Mode of access: Internet.

Report of the Special Counsel's investigation of allegations relating to the Bureau of Veterinary Medicine, Food and Drug Administration /

Cover title.

Tools for compliance for the medical device and in vitrol diagnostic product industries.

Mode of access: Internet.

From test tube to patient : new drug development in the United States.

Mode of access: Internet.

US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins

Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic therapy for patients with acute coronary syndromes. Each approved LMWH is a pleotropic biological agent with a unique chemical, biochemical, biophysical and biological profile and displays different pharmacodynamic and pharmacokinetic profiles. As a result, LMWHs are neither equipotent in preclinical assays nor equivalent in terms of their clinical efficacy and safety. Previously, the US Food and Drug Administration (FDA) cautioned against using various LMWHs interchangeably, however recently, the FDA approved generic versions of LMWH that have not been tested in large clinical trials. This paper highlights the bio-chemical and pharmacological differences between the LMWH preparations that may result in different clinical outcomes, and also reviews the implications and challenges physicians face when generic versions of the original/innovator agents are approved for clinical use.

Notices of judgment under the Food and drugs act.

Nos. 2986-15000, Aug. 3, 1914-June, 1927, issued as Supplements to Service and regulatory announcements of the Bureau of chemistry. Beginning with no. 3501, Apr. 3, 1915, Supplements are numbered consecutively S.R.A. Chem. suppl. 1-230.

The regulation of pesticides in the United States /

Cover title.

Parathion data presented to U.S. Food and Drug Administration, in the matter of: tolerances for poisonous or deleterious residues on or in fresh fruits and vegetables.

Cover-title.

FDA consumer nutrition knowledge survey : a nationwide study of food shopper's knowledge, beliefs, attitudes, and reported behavior regarding food and nutrition /

Includes bibliographical references.

FDA drug bulletin April 1970 through October 1990 ; FDA medical bulletin March 1991 through June 1993 : index by subject and title.

Mode of access: Internet.

Pesticide chemicals: regulations under the Federal food, drug, and cosmetic act.

Kept up-to-date by revised pages which are inserted.

Drugs--current good manufacturing practice in manufacture, processing, packing, or holding. : regulations under the Federal Food, Drug, and Cosmetic Act, Part 133, Title 21, Code of Federal Regulations. Part 191, Hazardous substances.

Mode of access: Internet.